12.01.07
A new in vitro study of Soy Labs’ (Fairfield, CA) Lunasin has demonstrated its potential to reduce cholesterol levels by inhibiting the expression of a gene known to be responsible for internal cholesterol production and increasing expression of a gene which reduces plasma LDL cholesterol. A recently discovered bioactive soy component, Lunasin is thought to be one of the key components in soy that is responsible for its cholesterol-lowering properties.
Cell culture of HepG2 liver cells showed Lunasin significantly reduced levels of HMG-CoA reducstase expression by 50%; HMG-CoA is the gene that produces the enzyme responsible for cholesterol biosynthesis. At the same time, expression of the gene, which produces LDL receptors that help to clear plasma cholesterol was increased by 60%.
The study was led by principal investigator Alfredo Galvez, PhD (Center of Excellence for Nutritional Genomics at the University of California, Davis). He is also lead scientific advisor for Soy Labs as well as an adjunct professor at the University of Missouri, Columbia.
Cell culture of HepG2 liver cells showed Lunasin significantly reduced levels of HMG-CoA reducstase expression by 50%; HMG-CoA is the gene that produces the enzyme responsible for cholesterol biosynthesis. At the same time, expression of the gene, which produces LDL receptors that help to clear plasma cholesterol was increased by 60%.
The study was led by principal investigator Alfredo Galvez, PhD (Center of Excellence for Nutritional Genomics at the University of California, Davis). He is also lead scientific advisor for Soy Labs as well as an adjunct professor at the University of Missouri, Columbia.